Cetuximab, a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has demonstrated efficacy and overall survival benefits in patients with K-Ras wild-type metastatic colorectal cancer (Cunningham et al, 2004; Sobrero et al, 2008). The gene discussed is KRAS; the disease is metastatic colorectal cancer.